TFEB and neoplasm: Cisplatin treatment induced TFEB nuclear translocation, increasing the expression of programmed cell death-ligands 1 and 2 (PD-L1 and PD-L2) to foster an immunosuppressive tumor microenvironment that mediates immune evasion and drug resistance [71].